The determination of serum thyroglobulin (Tg) is commonly used for detecting the presence of residual thyroid tissue or cancer recurrence in patients treated for differentiated thyroid cancer (DTC). The aim of the study was to evaluate the performance characteristics of a recently introduced fully automated chemiluminescent immunoassay, based on four monoclonal antibodies and which produces results in 40 min. Analytical sensitivity (0·01 µg/l) was computed from 20 replicates of the zero calibrator and of the 'Tg-free' sample pool. Functional sensitivity (0·1 µg/l at 20 coefficients of variation percent) was determined from the imprecision profile obtained by assaying ten serum pools. The reliability of the measurements in the low concentration range (Tg<1 µg/l) has been checked by progressive dilution with the 'Tg-free' serum of a sample pool at 5·27 µg/l; measured values were very close to the expected values (recovery 100-133%).
Introduction
Thyroglobulin (Tg) is a large glycoprotein (molecular weight=660 000) stored in the follicular colloid of the thyroid gland. It acts as a prohormone in the intra-thyroid synthesis of thyroxine (T4) and triiodothyronine (T3) and it is produced only by normal thyrocytes or welldifferentiated thyroid cancer cells. Since the thyroid is the only source of Tg, a rise in Tg levels in patients after total thyroidectomy and radioiodine ablation of residual thyroid tissue indicates the recurrence of differentiated thyroid cancer (DTC). In this context, a strong correlation between serum Tg levels and the amount of differentiated thyroid tissue has been reported (Ozata et al. 1994 , Duren et al. 1999 , Pacini & Pinchera 1999 , Girelli & De Vido 2000 . It is recognized worldwide that the measurement of circulating Tg represents a fundamental tool in the management and follow-up of patients affected by DTC (Schlumberger 1998 , Mazzaferri 1999 ). In addition, in a very recent Tg consensus conference (Mazzaferri et al. 2003) , a surveillance guideline has been extended to the use of thyrotrophin (TSH)-stimulated Tg levels for thyroidectomized patients without clinical evidence of residual tumour with Tg values below 1 µg/l during TSH suppression. The detection limit of the methods is critical to detect small amounts of Tg and to observe a change in Tg concentration. It has been proposed that only methods providing the greatest distinction between the lower limit of the euthyroid reference range and the functional sensitivity limit of the assay offer the best clinical sensitivity for detecting small amounts of thyroid tissue in the TSH-suppressed state (Spencer et al. 1996) . On the other hand, it is noteworthy that, despite the substantial clinical use of Tg measurement, wide differences still remain between results produced in different laboratories because of poor standardization, the heterogeneity of circulating Tg, interference from anti-Tg autoantibodies (AbTg), differences in the epitope recognition by the different antibodies used in the different assays (Zucchelli et al. 1996) and interference from heterophile antibodies.
For these reasons, highly sensitive, precise and accurate Tg assays are needed in the follow-up of patients with DTC even if this goal is technically challenging (Spencer et al. 1996 , 1997 , Clark & Beckett 2002 , Demers & Spencer 2002 ). In the last 30 years, the analytical sensitivity of Tg measurement has been greatly improved, being about 5 µg/l with the first traditional radioimmunoassays (Van Herle et al. 1973 ) and 0·01-0·02 µg/l with the recently developed immunoassay based on enzyme (Wunderlich et al. 2001 , Zophel et al. 2003 or chemiluminescent tracer (Pressner et al. 2003) . Thus, some methods can now achieve very good analytical and functional sensitivity giving reliable results in the very low concentration range. In addition, with the advent of fully automatized assays, such as the technique recently developed by Beckman Coulter on the Access analyzer, results are readily available to the clinician in less than 1 h while patients are still in the hospital.
In the present study, the analytical and clinical performance of the Tg Beckman Coulter assay on the Access analyzer were evaluated and compared with other known and substantially used immunoassays.
Materials and Methods

Assay method
The Tg Access immunoassay (Tg Access) (Beckman Coulter, Brea, CA, USA) is a chemiluminescent fully automated technique where samples can be processed at any time in a 'random access' format. The serum sample reacts with a biotinylated mixture of four monoclonal anti-Tg antibodies, streptavidin-coated paramagnetic particles and monoclonal anti-Tg antibody conjugated with alkaline phosphatase. The biotinylated antibodies and Tg in the serum bind to the solid phase, while the conjugated antibody reacts with a different antigenic site on the Tg molecule. After incubation and washing to remove material not bound to the solid phase, immobilized Tg is detected by the addition of a chemiluminescent enzyme substrate (see Fig. 1 ). The light generated is measured as relative light units (RLU) with a luminometer. Tg concentration is determined by a stored multipoint response curve calibrated to CRM 457 international reference preparation using a smoothing spline mathematic model (Feldt-Rasmussen & Schlumberger 1988) . The time to the first result is about 40 min; sustained throughput is 100 tests/h.
The assay system was calibrated according to the manufacturer's instructions every 56 days throughout the course of the study. The calibration curve ranged from 0 to 480 µg/l; in the range 0-1 µg/l, the analytical response (RLU) showed a good improvement from approximately 9000 RLU (standard at 0 µg/l) to approximately 45 000 RLU (standard at 0·93 µg/l), namely a ratio of 5, as reported in Fig. 2 , thus indicating that the assay achieves good precision in the low concentration range.
In this study, patients with positive AbTg, measured using a two-step immunoenzymometric assay commercial kit performed on an AIA-21 analyser (Tosoh Bioscience, Tokyo, Japan), were excluded to rule out possible interference in the Tg assay; the minimal detectable concentration of AbTg was estimated to be 12 IU/ml, samples with AbTg<12 IU/ml were considered negative.
Analytical performance
Detection limit
The minimum detectable concentration (namely the detection limit or the analytical sensitivity), defined as the Tg value corresponding to a signal 3 S.D. above the mean of 20 replicates of the zero calibrator (0 µg/l Tg; Beckman) and of a Tg-free serum from thyroidectomized patients, was determined. Within-assay imprecision Four serum samples were assayed in five replicates in the same run and the relative C.V. values were calculated (within-assay imprecision).
Imprecision profile
AbTg inteference Five serum samples from subjects without AbTg and containing a measurable concentration of Tg (range from 3·10 to 12·6 µg/l, mean 6·98 µg/l) were diluted with serum from a thyroidectomized and radioiodine-ablated patient (as a treatment for papillary carcinoma, stage I) who had been disease free for more than 10 years, affected by Hashimoto's thyroiditis, with Tg Access<0·01 µg/l, but with slightly positive AbTg values (about 150 IU/ml); another five samples without AbTg and containing a measurable concentration of Tg (range from 3·94 to 23·8 µg/l, mean 12·3 µg/l) were diluted with a serum pool containing AbTg (about 300 IU/ml) and Tg<1 µg/l. The ten diluted sera, with a final AbTg concentration of 110 IU/ml (first group) and 220 IU/ml (second group), were assayed to check for interference by AbTg in the Tg Access assay.
Dilution test
The reliability of Tg measurements in the low concentration range (<1 µg/l) was tested by progressively diluting a sample pool at 5·27 µg/l with Tg-free serum obtained from thyroidectomized and radioiodine-ablated DTC, stage 1, disease-free patients.
Normal range Tg concentrations were measured in the sera of 120 healthy AbTg-negative euthyroid individuals (mean age 22 8 years, 69 males and 51 females; TSH range 0·4-3·9 µU/ml, mean 1·67 µU/m; free T3 range 2·1-3·2 pg/ml, mean 2·35 pg/ml; free T4 range 7·1-18·0 pg/ml, mean 12·0 pg/ml), without a personal or family history of thyroid disease and with a normal thyroid pattern at ultrasonographic examination.
Heterophile antibody interference
Interference by heterophile antibodies was checked by using heterophileblocking tubes (HTB; Scantibodies, Santee, CA, USA) according to the procedure suggested recently (Pressner et al. 2003) and Tg measurements were repeated after incubating 500 µl of each serum at room temperature for 1 h.
Method comparison Tg Access measurements were compared with a traditional widely used immunoradiometric assay (IRMA) produced by Pasteur (Gif-SurYvette Cedex, France) based on a mixture of four monoclonal anti-Tg antibodies such as were used in the Tg Access assay.
Clinical performance
To estimate the upper reference limit (cut-off) for DTC recurrence, 53 patients (47 women and six men aged 53 14 years (means S.D.)) were enrolled in the study. All of these patients had undergone total thyroidectomy and radioiodine ablation for primary treatment of stage I DTC, they had been 'disease-free' for more than 10 years and underwent routine follow-up at the time of the study. Stimulation with recombinant human TSH (rhTSH) was performed for routine follow-up in 22 consecutive unselected treated patients with DTC, and Tg was measured in basal conditions during suppressive therapy and 5 days after rhTSH.
This study was approved by our Institutional Ethics review Committee. Informed consent was obtained from all patients.
Statistical analysis
Continuous variables are expressed as means S.D., a P value less than 0·05 was considered statistically significant.
Deming regression was used to calculate analytical correlation between different methods; agreement between methods was assessed by the Bland and Altman plot (Cornbleet & Gochman 1979 , Bland & Altman 1986 , 1999 .
Results
Analytical performance
Detection limit The detection limit was found to be 0·007 µg/l using the zero standard (0 µg/l Tg; Beckman) and 0·012 µg/l using Tg-free serum and therefore a detection limit of 0·01 µg/l was assumed. For comparison, the detection limit calculated for the Pasteur IRMA using Tg-free serum was 0·54 µg/l (declared 0·2 µg/l).
Imprecision profile
The imprecision profile (C.V. values) performed using ten different serum pools was as follows: 26·8% at 0·061 µg/l, 14·4% at 0·14 µg/l, 13·8% at 0·31 µg/l, 11·3% at 0·65 µg/l, 9·6% at 0·93 µg/l, 7·6% at 3·1 µg/l, 6·7% at 9·6 µg/l, 4·3% at 36·2 µg/l, 4·3% at 64·8 µg/l, 4·3% at 168 µg/l; functional sensitivity was 0·1 µg/l at 20% C.V.
Within-assay imprecision The C.V. values were 2·7% at 0·18 µg/l, 1·3% at 0·37 µg/l, 1·5% at 0·56 µg/l and 2·0% at 0·75 µg/l. AbTg interference Mean recovery, estimated after adding sera containing AbTg to sera with Tg, was 63·8 16% (observed values versus expected values), thus indicating that the Tg Access assay, like other methods, was affected by interference from AbTg (Erali et al. 1996) .
Dilution test Tg concentrations measured in samples progressively diluted with Tg-free serum were found to be very close to the expected values (recovery 100-133%) in the low concentration range and showed very good linearity (Fig. 3) . The dilution test was also performed with the Tg Pasteur assay where only the first five diluted samples showed values above its detection limit (0·2 µg/l) and the bias between observed and expected values was very high.
Normal range In normal subjects, Tg ranged from 2·55 to 64·3 µg/l, with a median of 11·16 µg/l and a 95th percentile concentration of 46·9 µg/l. This result is in agreement with the suggested reference interval (NACB guidelines approximately 3-40 µg/l; Demers & Spencer 2002) .
Method comparison
Comparison between the Access assay and the Pasteur IRMA was carried out on 64 samples and Deming regression analysis gave: Tg Access= 1·1+0·61 Tg Pasteur, r=0·99, P<0·001 (Fig. 4) .
Clinical performance
The cut-off at the 99th percentile of 53 long-term 'disease-free' patients previously treated for stage I DTC during suppressive -T4 therapy was 0·16 µg/l; five patients had Tg values below the assay detection limit (<0·01 µg/l), whereas 48 patients showed a measurable Tg concentration up to 0·19 µg/l (Fig. 5) .
Tg measurements before (i.e. during suppressive therapy) and after (5 days) of rhTSH stimulation was performed in 22 sera obtaining different patterns of response. The main clinical and serological data are reported in Table 1 . In 68% of patients (15/22), basal Tg values were<0·1 µg/l: in 80% of these patients (12/15) Tg remained<0·1 µg/l also after rhTSH stimulation and only 1/12 had a positive whole body scan (WBS), while in 20% (3/15) Tg levels showed an increment but were always<1 µg/l with 1/3 having a positive WBS. In the other 32% of patients (7/22), Tg levels were>0·1 µg/l also in basal conditions; after rhTSH stimulation Tg was always detectable but there were two different patterns of response: 57% showed an increment of Tg values (4/7), with a positive WBS in 1/4, while 43% showed a suspicious lack of response (3/7).
Interference by heterophile antibodies was tested in patients 77/F, 57/F and 46/M shown in Table 1 . These three patients had detectable basal Tg (0·22, 0·79 and 2·77 µg/l respectively) but showed a lack of rhTSHstimulated response (0·20, 0·66 and 2·61 µg/l respectively). In patient 77/F, Tg levels were also confirmed after the incubation of sera in HBT tubes (basal Tg 0·21 µg/l and after rhTSH 0·28 µg/l). In the other two patients, Tg levels dropped to 0·01 µg/l after incubation in HBT tubes, thus indicating a substantial interference by heterophile antibodies in the Tg Access assay. For comparison, further experiments in three unselected sera (Tg concentration of 0·71, 4·12 and 10·7 µg/l) did not show any interference after incubation in HBT tubes (Tg values of 0·59, 4·14 and 11·9 µg/l respectively).
Discussion
Tg measurement is considered the best biochemical marker worldwide for detecting persistent or recurrent diseases in the follow-up of patients affected by DTC (Kendall-Taylor 2003) ; the fundamental role of this assay is indirectly reinforced by the data from several recent 
Figure 5
Distribution of 53 patients who had undergone total thyroidectomy and radioiodine ablation for primary treatment of stage I DTC and who had been disease free for more than 10 years; five patients had Tg values below the assay detection limit (0·01 g/l) whereas 48 patients showed a Tg concentration up to 0·19 g/l. Functional sensitivity and cut-off at the 99th percentile are indicated. studies (Hardy et al. 1995 , Schlumberger & Baudin 1998 , Teppo & Hakulinen 1998 , Vanderpump et al. 1998 , Spencer et al. 1999 , Kumar et al. 2001 , Torens & Burch 2001 .
Theoretically, an ideal biomarker should be highly sensitive and specific and should be able to be reproduced across different clinical laboratories. The inherent error in the measurement itself (C.V.) should be sufficiently low that small changes in the level of the biomarker reflect true changes in the clinical status of the patient. Finally, the assay should be relatively easy to perform and analyze so that the information is readily available to the clinician.
Tg assay performed with the Access analyzer as evaluated in our laboratory appears to satisfy most of these characteristics, providing analytical and clinical performance comparable with the most commonly used methods. This method permits a lower detection limit (0·01 µg/l), a lower functional sensitivity (0·1 µg/l) and a lower cut-off for patients with DTC (0·16 µg/l); the latter, in particular, was sixfold lower than that reported in the latest guidelines (Mazzaferri 1999 , Mazzaferri et al. 2003 . These results are even better than those found recently (Giovanella & Ceriani 2002) . In addition, Tg Access is fast (40 min), feasible, simple, technically undemanding and potentially accessible to all medical centres contrary to the previous radioactive (IRMA) methods. The clinical importance of a reliable and accurate Tg determination is even more emphasized by the recent use of Tg measurements after rhTSH stimulation. Actually, serum Tg measured during TSH stimulation (endogenous TSH or rhTSH) is more sensitive than the basal Tg value obtained during -T4 treatment (Haugen et al. 1999) ; using this approach the presence of cancer is identified before diagnostic 131 I WBS can localize the tumour (Cailleux et al. 2000 , Mazzaferri & Kloos 2000 , Pacini et al. 2001 , Haugen et al. 2002 , Pellegriti et al. 2003 . Interesting clinical conclusions can be drawn from the results of our pilot study on the use of Tg Access measurements during suppressive therapy and after rhTSH stimulation. In all patients with Tg<0·1 µg/l during suppressive -T4 therapy, Tg after rhTSH remained<1 µg/l or, in 80% of these patients, Tg levels remained<0·1 µg/l after the rhTSH. These data indicated that the Tg Access assay could also be useful in the very low concentration range (<0·1 µg/l) during suppressive L-T4 treatment, being able to discriminate low-risk patients. These preliminary findings show the high sensitivity of Tg measurements in the follow-up of low-risk patients with DTC, not only after rhTSH stimulation but also during suppressive therapy. The Tg Access assay therefore seems to give very good clinical sensitivity (no false-negative patients) and specificity (no false-positive patients). This could be useful for choosing better and less aggressive protocols. At the moment, the commercially used Tg assays are not able to discriminate small differences in the low concentration range, Tg results below 1 µg/l are considered to be in the 'grey' zone. Tg Access measurement could then be useful in the clinical assessment of patients to be submitted to 131 I WBS; in fact the usefulness of WBS after rhTSH when Tg values remain below 1 µg/l, now considered to be the gold standard for sensitivity (Torlontano et al. 2003 , Koh et al. 2003 , is still controversial.
Our results on AbTg interference, even though obtained in a limited number of patients, demonstrated that Tg determination was affected by the presence of AbTg using the Tg Access method. For this reason, in all samples where Tg concentration was measured in our laboratory, we also measured AbTg concentrations and when AbTg was positive we considered the Tg value to be not reliable. Besides the interference by AbTg which produced false-negative results, the assay was also interfered with by heterophile antibodies which produced false-positive results, in agreement with a previous report on Tg Access assay performance (Pressner et al. 2003) . However, we wish to point out that the problem of antibody interference in Tg measurement is still a problem which affects any commercially available method (Demers & Spencer 2002 ).
In conclusion, Access Tg measurement could represent an improvement in terms of analytical sensitivity and precision when compared with the most widely employed assays. Moreover, the very good practicality of this test makes its routine application even easier. Further retrospective and prospective studies in a large series of patients treated for DTC will indicate its real usefulness in clinical practice.
